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Abstract
To identify genetic loci influencing central obesity and fat distribution, we performed a meta-analysis of 16 genome-wide
association studies (GWAS, N=38,580) informative for adult waist circumference (WC) and waist–hip ratio (WHR). We
selected 26 SNPs for follow-up, for which the evidence of association with measures of central adiposity (WC and/or WHR)
was strong and disproportionate to that for overall adiposity or height. Follow-up studies in a maximum of 70,689
individuals identified two loci strongly associated with measures of central adiposity; these map near TFAP2B (WC,
P=1.9610
211) and MSRA (WC, P=8.9610
29). A third locus, near LYPLAL1, was associated with WHR in women only
(P=2.6610
28). The variants near TFAP2B appear to influence central adiposity through an effect on overall obesity/fat-mass,
whereas LYPLAL1 displays a strong female-only association with fat distribution. By focusing on anthropometric measures of
central obesity and fat distribution, we have identified three loci implicated in the regulation of human adiposity.
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The accumulation of abnormal amounts of intra-abdominal fat
(central adiposity) is associated with serious adverse metabolic and
cardiovascular outcomes, including type 2 diabetes (T2D) and
atherosclerotic heart disease [1]. Indeed, because the medical
consequences of increasing fat mass are disproportionately
attributable to the extent of central adiposity, measures of overall
adiposity, such as body mass index (BMI), fail to capture all of this
risk [2,3].
Measures of central and overall adiposity are highly correlated
(BMI has r
2,0.9 with waist circumference [WC] and ,0.6 with
waist-hip ratio [WHR], Table S1). WC and WHR are correlated
with more precise measures of intra-abdominal fat measured by
MRI in obese women (r
2,0.6 and 0.5, respectively) [4]. Several
lines of evidence indicate that individual variability in patterns of
fat distribution involves local, depot-specific processes, which are
independent of the predominantly neuronal mechanisms that
control overall energy balance. First, anthropometric measures of
central adiposity are highly heritable [5] and, after correcting for
BMI, heritability estimates remain high (,60% for WC and
,45% for WHR) [6]. Second, there are substantial gender-specific
differences in fat distribution, and these appear to reflect genetic
influences [7]. Third, uncommon monogenic syndromes (the
partial lipodystrophies) demonstrate that DNA variants can have
dramatic effects on the development and/or maintenance of
specific regional fat-depots [8].
Efforts to identify common and rare variants influencing BMI
and risk of obesity have emphasized the key role of neuronal
(hypothalamic) regulation of overall adiposity [9–17] but provided
few clues to processes that are specifically responsible for individual
variation in central obesity and fat distribution. Definition of the
mechanisms involved in the regulation of fat distribution in general,
and visceral fat mass in particular, is therefore key to understanding
obesity and its accompanying morbidity and mortality. Given the
challenges associated with the pharmacological manipulation of
hypothalamic processes, the identification of pathways influencing
abdominal fat accumulation would also present novel opportunities
for therapeutic development.
With this in mind, we set out to identify genetic loci influencing
anthropometric measures of central obesity and fat distribution,
namely, WC and WHR. Our meta-analysis of 16 genome wide
association studies (GWAS), followed by large-scale replication
testing, generating a combined sample of up to 118,691 individuals
of European origin, has identified three loci associated with these
critical biomedical traits.
Results/Discussion
Our strategy for identifying common variants influencing
central adiposity is summarized in Figure 1. The study was based
on an initial (‘‘stage 1’’) meta-analysis of GWAS data to identify
SNPs strongly-associated with measures of central adiposity (see
Table S2). We then focused our ‘‘stage 2’’ follow-up efforts on the
subset of those signals for which the strength of the evidence of
association for measures of central adiposity (WC and WHR)
appeared to be substantially stronger than that observed for overall
adiposity and/or height. We reasoned that this subset of signals
would be enriched for variants with preferential influences on
central fat accumulation.
GWAS Meta-Analysis for Anthropometric Measures of
Central Obesity
The stage 1 meta-analysis combined data from 16 GWAS scans
(N=38,580, all of European ancestry) informative for anthropo-
metric phenotypes (Table S3). We selected two complementary
but related measures of central adiposity for analysis: waist
circumference (WC) and waist-hip ratio (WHR) (Table S4). In
total, 2,573,738 directly typed or imputed SNPs were tested for
association using regression analysis under an additive model (see
Table S5 for details). We conducted a weighted Z-score meta-
analysis combining gender- and sample-specific association P-
values gathered from each contributing study. We also performed
an inverse-variance meta-analysis using regression results (b-
estimates and standard errors) after applying uniform analysis
procedures across all contributing samples. The results of the two
meta-analyses were highly-congruent. Here, we report association
P-values based on the former, as it was the first-completed and was
used to select SNPs for follow-up genotyping. Reported effect-size
estimates derive from the latter (see Methods for further details).
The individual studies as well as the results from the overall
meta-analysis were corrected for residual inflation of the test
statistic using genomic control methods [18]. The overall genomic
control lambda (lGC) in the mixed-gender analysis were
lGC_WC=1.09 (lGC_WC_1000=1.003 [standardised to a sample
size of 1000]) and lGC_WHR=1.07 (lGC_WC_1000=1.002) (see
Text S1) [19]. From these data, we identified a set of 76 SNPs (one
per independent region of association, based on an arbitrary
follow-up P-value threshold of 10
25 in preliminary pre-GC
corrected analyses) that showed evidence of association to one or
both of the traits (Figure 2). As might have been expected given the
strong correlations between measures of central adiposity and
BMI, the most significant associations for WC and WHR were
observed for SNPs mapping near FTO (rs1421085, WC,
P=3.7610
220) and MC4R (rs17700144, WC, P=6.2610
211).
These two markers are highly correlated (r
2.0.8) with markers
that represent two of the strongest signals for overall adiposity
(Table S10) [9–10,12–14,16–17,20].
In Silico and De Novo Follow-Up
From this initial set of 76 WC- and/or WHR- associated
signals, we sought to enrich for variants with specific impacts on
central adiposity, by identifying a subset of 23 SNPs for which
there was greatest evidence for a disproportionate effect on
central adiposity, as opposed to overall adiposity or height.
These 23 variants all had strong (i.e. P#10
25) associations with
Author Summary
Here, we describe a meta-analysis of genome-wide
association data from 38,580 individuals, followed by
large-scale replication (in up to 70,689 individuals)
designed to uncover variants influencing anthropometric
measures of central obesity and fat distribution, namely
waist circumference (WC) and waist–hip ratio (WHR). This
work complements parallel efforts that have been
successful in defining variants impacting overall adiposity
and focuses on the visceral fat accumulation which has
particularly strong relationships to metabolic and cardio-
vascular disease. Our analyses have identified two loci
(TFAP2B and MSRA) associated with WC, and a further
locus, near LYPLAL1, which shows gender-specific relation-
ships with WHR (all to levels of genome-wide significance).
These loci vary in the strength of their associations with
overall adiposity, and LYPLAL1 in particular appears to have
a specific effect on patterns of fat distribution. All in all,
these three loci provide novel insights into human
physiology and the development of obesity.
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association with overall adiposity (BMI, P.0.01) or adult height
(P$0.005) in the stage 1 GWAS meta-analysis data (Table S2).
We also included three variants for reasons of biological
candidacy, even though they did not precisely meet all P-value
threshold criteria (see Table S2). Given the stage 1 sample size of
38,580, the follow-up P-value threshold of 10
25 provides 80%
power to detect a per-allele beta of 0.045 (equivalent, for
example, to a per-allele effect on WC of approximately 0.5 cm),
given an additive model and MAF of 20%.
Figure 1. Project outline. We started out with a meta-analysis of GWAS data from 16 cohorts comprising 38,580 individuals informative for WC and
37,670 for WHR. We selected 23 SNPs of our top signals based on the following criteria (Table S2): preliminary stage 1 meta-analysis P-value#10
25,
BMI P-value.0.01 and height P-value.5610
23. We supplemented these 23 independent loci (r
2,0.2) SNPs with three additional candidate signals.
Further, we excluded recently reported BMI loci (Table S10) [10,14,16–17]. These 26 SNPs were followed up in our stage 2 samples (N=maximum of
70,689 individuals). Further, we sought to confirm WC signals reaching genome wide significance in the combined analysis of stage 1 and 2 data in
GWA data from the CHARGE consortium (for which WHR was not available). The data from the Rotterdam and ERF cohorts (up to 6,702 individuals)
which were included in both CHARGE and stage 2 data, were counted only once in the overall analysis.
doi:10.1371/journal.pgen.1000508.g001
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another 8 studies with GWAS data (Stage 2a: maximum
N=13,830 individuals, all European-ancestry), and performed de
novo genotyping in subjects from 20 additional studies (Stage 2b:
maximum N=56,859, all European-ancestry) (Table S3). Follow-
up analyses were restricted to the precise phenotype(s) (WC and/
or WHR) for which the SNP had been selected in stage 1 making a
total of 30 SNP-phenotype combinations (Tables S2 and S6).
After combining gender- and study-specific measures of
association across all studies (maximum possible N=109,269:
Tables S2 and S3), we identified three signals reaching genome-
wide levels of significance in the joint analysis of stage 1 and stage
2 data (P,5610
28, Table 1, Figure 3). In all three instances, the
association was observed with WC. The first (rs987237, chromo-
some 6p12: P=4.5610
29) maps near TFAP2B, which encodes
transcription factor activating enhancer-binding protein 2 beta.
The second (rs7826222, chromosome 8p23.1: P=1.2610
28)
resides near MSRA, encoding methionine sulfoxide reductase A,
whilst the third (rs6429082, chromosome 1q42.3: P=2.6610
28)i s
located within the TBCE (tubulin folding cofactor E) gene region.
Confirmation in CHARGE Consortium GWAS Data
As a final stage of confirmation, we analysed genotype data for
rs987237, rs7826222 and rs6429082 made available to us by the
CHARGE consortium, whose members had recently completed a
GWAS meta-analysis of WC in 31,375 individuals (of which up to
6,702 individuals were overlapping with samples from our stage 2
and were removed before the joint meta-analysis).
At TFAP2B, CHARGE analyses revealed directionally-consis-
tent association with WC (rs987237, N=31,372, P=3.6610
24)
resulting in a combined P-value of 1.9610
211 (N=118,691). At
MSRA, genotypes for rs7826222 could only be imputed in a subset
(N=8,097) of CHARGE samples (this reflects SNP nomenclature
issues rather than data quality – see Text S1). Nonetheless, the
effect in CHARGE was directionally consistent (P=0.28), and in
Figure 2. Genome-wide association results for GIANT (Stage 1). A. Manhattan plots showing significance of association of all SNPs in the
Stage 1 GIANT meta-analysis with central obesity phenotypes. SNPs are plotted on the x-axis according to their position on each chromosome against
association with central obesity measure (WC or WHR) on the y-axis (shown as 2log10 P-value). SNPs that have been previously reported to show
association with BMI is shown in blue [10,14,16] and the two regions showing strong associations in the overall, non-gender-stratified analyses are
shown in green. Other SNPs taken forward into stage 2 follow-up are indicated in red. B. Quantile-quantile (QQ) plots of SNPs; after Stage 1 GIANT
meta-analysis (black) and after removing any SNPs surrounding the recently reported BMI loci [10,14,16–17] (blue). The grey areas in the QQ plots
represent the 95% confidence intervals around the test statistics and after excluding the recently reported BMI loci [10,14,16–17], there is no
indication of excess of signal.
doi:10.1371/journal.pgen.1000508.g002
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association with WC was improved (P=8.9610
29) (Table 1).
In contrast, rs6429082 in TBCE showed no evidence of
association with WC in the full CHARGE data set (N=31,373,
P=0.12). Since analysis of the combined data set no longer
reached genome-wide significance (P=2.9610
27), further studies
will be required to establish the status of this signal. For the
TFAP2B and MRSA loci, there was no evidence of heterogeneity of
effect size across the various sample sets, and no evidence that the
inclusion of diabetes or coronary artery disease case samples had
any impact on the associations (Table S2).
Gender-Specific Association Analyses
Given the clear gender dimorphism of central obesity, and
evidencethatsome geneticeffectsonfatdistributionmaybe gender-
specific [7], we reanalysed the stage 1 GWAS data, looking for
Figure 3. Regional plots of loci highlighted in this study. SNPs are plotted by position on chromosome against association (2log10 p-value)
with central obesity phenotype (WC or WHR) using stage 1 (GWAS meta-analysis) data. In the case of panel (b), analyses are restricted to women only.
In each panel, the SNP with the strongest association based on stage 1 data is denoted with a purple diamond: the P-value attached represents the
final P-value attained across all available data (Table 1). Estimated recombination rates (from HapMap-CEU) are plotted in purple to reflect the local
LD structure on a secondary Y-axis. The SNPs surrounding the most significant SNP (purple diamond) are color-coded (see inset) to reflect their LD
with this SNP (using pair-wise r
2 values from HapMap CEU). Genes and the position of exons, as well as the direction of transcription, are shown
below the plots (using data from the UCSC genome browser, genome.ucsc.edu). The grey area marks the extent of the region that includes any SNP
with r
2$0.3 relative to the SNP with the strongest stage 1 association signal. Hash marks represent SNP positions on each genotyping array used by
any individual study and also show SNP positions after imputation.
doi:10.1371/journal.pgen.1000508.g003
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further locus of interest. SNPs, including rs2605100, within a gene
desert on chromosome 1q41 (138 kb from ZC3H11B and 259 kb
from LYPLAL1, encoding lysophospholipase-like protein 1) had
shown modest evidence for association with WHR in our primary
(both genders included) analysis (P=3.6610
26) (Table S2).
However, in gender-specific analyses, this association was clearly
restricted to females (P=1.3610
28; males: P=0.50). When stage 1
and stage 2 data were combined, the female-only signal remained
highly-significant (P=2.6610
28) (Table 1) with evidence of effect-
size heterogeneity between genders (P=1.1610
23). As the
CHARGE GWAS analyses were restricted to WC, we were unable
to follow-up the LYPLAL1 signal in these data.
Disentangling Effects on Overall and Central Adiposity
We had designed this study to be complementary to equivalent
analyses of overall adiposity (as measured by BMI) conducted on
many of the same samples [10,12–14,16,17]. By focusing on
widely-available anthropometric proxies of central adiposity, and
targeting replication to those signals which, in the GWAS data,
had the most compelling evidence for disproportionate effects on
central adiposity, our aim had been to enrich for variants
influencing regional rather than overall obesity, and thereby
overcome the very strong correlations between these measures.
We were interested therefore in establishing the extent to which
the confirmed, genome-wide associations identified at/near
TFAP2B, MSRA and LYPLAL1 were indeed specific for central
fat accumulation as opposed to being driven by other highly-
correlated anthropometric traits (most notably overall adiposity as
measured by BMI). To evaluate this, we used data from the stage 2
replication samples, from which we can expect to obtain less
biased estimates of the relative effects across anthropometric
phenotypes.
In the case of TFAP2B, these stage 2 data indicated that,
notwithstanding the evidence for discordant effects in the stage 1
data (which led to its selection for follow up), rs987237 showed
strong associations with overall adiposity (P=7.0610
212 for BMI
in stage 2 alone). The association with WC remained only
nominally significant in stage 2 (P=0.02) after adjustment for
BMI. The TFAP2B rs987237 G allele was weakly associated with
overall fat mass (0.15% difference per-allele [P=0.02] in 29,316
individuals with bioimpedance data; 0.25% difference per-allele
[P=0.02] in 13,039 additional individuals with dual energy X-ray
absorptiometry (DXA) measures: Table S7). In the 7,346
Table 1. SNPs with genome-wide significant evidence for association with central adiposity and fat distribution.
Locus
(Chromosomal
Region)
SNP (Effect/
Non-Effect)
Effect allele
frequency (EAF)
% Phenotype Gender Stage N* b (SE)
Z-
score P-value**
Stage 1 38,635 0.038 (0.010) 3.87 1.10610
24
Stage 2a 12,369 0.019 (0.017) 1.13 2.57610
21
TFAP2B (6p12) rs987237 16.4% WC both Stage 2b 43,016 0.037 (0.009) 4.24 2.22610
25
(G/A) Stage 1+2 Combined 94,021 0.035 (0.006) 5.86 4.54610
29
CHARGE 31,372 - 3.57 3.64610
24
Overall 118,691 - 6.72 1.87610
211
Stage 1 36,865 0.045 (0.011) 4.36 1.32610
25
Stage 2a 3,406{ 0.023 (0.033) 0.73 4.63610
21
MSRA (8p23.1) rs7826222 18.3% WC both Stage 2b 31,841 0.036 (0.011) 3.47 5.31610
24
(G/C) Stage 1+2 Combined 72,113 0.040 (0.007) 5.7 1.20610
28
CHARGE 8,097{ - 1.09 2.76610
21
Overall 80,210 - 5.75 8.89610
29
Stage 1 21,397 0.062 (0.011) 5.69 1.30610
28
Stage 2a 6,021 0.035 (0.019) 1.74 8.17610
22
LYPLAL1 (1q41) rs2605100 69.2% WHR women Stage 2b 20,213 0.018 (0.011) 1.69 9.06610
22
(G/A) Stage 1+2 Combined 47,633 0.040 (0.007) 5.57 2.55610
28
CHARGE - - - -
Overall - - - -
Alleles: the first allele listed in the parenthesis is the effect allele, for which the allele frequency is given.
Stage 1: data from stage 1 GIANT GWAS meta-analysis.
Stage 2a: data from meta-analysis of in silico studies.
Stage 2b: data from meta-analysis of de novo genotyped studies.
Stage 1+2: data from stage 1 GIANT analyzed with in silico studies (Stage 2a) and de novo genotyped studies (Stage 2b).
Overall: data from meta-analysis of Stage1, 2a, 2b and CHARGE.
*Total sample sizes do not always reflect the sum of component studies due to (a) rounding errors in non-integeric sample sizes arising from the weighting procedure;
(b) overlap, for some markers, of data from the Rotterdam and ERF cohorts (up to 6,702 individuals) which were included in both CHARGE and stage 2 data, but which
are counted only once in the overall analysis.
**P-values: all P-values we report here are two-sided.
{For the MRSA locus, genotypes for rs7826222 were only available for a subset of the CHARGE samples (N=8,097). This is likely due to the fact that this SNP has been
renamed to rs545854 in NCBI build 36 and was consequently one of the SNPs omitted from HapMap release 22 and therefore is not present in build 36 imputations
based on that release of HapMap.
- Data not available. Effect size estimates and overall WHR results are not available as CHARGE only analysed WC using the weighted Z-score method (see Methods).
doi:10.1371/journal.pgen.1000508.t001
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there was no apparent association with percent central fat mass
(P=0.98), although this analysis is underpowered.
These data suggest that the chromosome 6p12 signal exerts its
predominant effect on fat accumulation at multiple sites, a finding
consistent with the known biology of TFAP2B, which is the most
obvious candidate gene in the locus. TFAP2B encodes a
transcription factor preferentially expressed in adipose tissue,
and over-expression of the transcript in 3T3L1-adipocytes leads to
insulin sensitivity via enhanced glucose transport and increased
lipid accumulation [21,22]. Over-expression of TFAP2B also
down-regulates expression of the insulin-sensitizing hormone
adiponectin by direct transcriptional repression [23]. Genetic
variants within TFAP2B have recently been reported to correlate
positively with TFAP2B transcript levels in adipose tissue [24].
Thus, TFAP2B can be added to the growing list of loci influencing
overall adiposity [10,14,16,17]. However, in contrast to most of
the variants previously implicated in monogenic or multifactorial
forms of obesity, which exert their effects on overall adiposity at
the hypothalamic level [10,12–14,16–17], TFAP2B may be
involved in global adipocyte response to positive energy balance.
In contrast, the signal on chromosome 1q41 (near LYPLAL1)
showed relatively modest associations with overall obesity (stage 2,
women only, P=1.9610
24 for BMI) and WC (P=0.01).
Crucially, the strength of the association with WHR was
substantially greater after adjustment for BMI (stage 2, women
only, P=4.3610
26). In the limited subset of women (N=7,228)
for whom direct measures of hip circumference (HC) could be
retrieved, and in whom there was a proportionate signal for WHR
(P=5.2610
24), we found no association with HC (P=0.7) and a
directionally consistent trend of association to WC (P=0.06).
Whilst these data would suggest that the LYPLAL1 signal does
indeed have a specific effect on fat distribution, our own DXA data
on regional fat distribution are non-contributory (N=5,455)
(Table S7), and large-scale clinical imaging studies will be required
to explore this further. The obvious candidate within this locus
(although it lies ,259 kb downstream of the most strongly-
associated variant) is LYPLAL1. This gene encodes a lysopho-
spholipase-like 1 protein thought to act as a triglyceride lipase and
reported to be up-regulated in subcutaneous adipose tissue of
obese subjects [25].
Biological connections between the MSRA locus and adiposity
phenotypes are unclear at this stage. The signal near MSRA
showed only weak association with overall adiposity (P=2.2610
23
for BMI in stage 2), but the strong association with WC in stage 2
samples became non-significant after BMI-adjustment (P=0.11).
The main proposed function of MSRA is to repair oxidative
damage to proteins by enzymatic reduction of methionine
sulfoxide. An alternative candidate in the vicinity is TNKS, which
encodes a TRF1-interacting ankyrin-related ADP-ribose polymer-
ase (tankyrase). Tankyrase is a peripheral membrane protein
known to interact with insulin-responsive aminopeptidase (IRAP)
in GLUT4 vesicles in adipocytes [26,27]. Thus TNKS has a
putative role in insulin-regulated glucose disposal into fat and
other tissues.
Variance Explained by the Associated Loci
We estimated the variance in these traits attributable to the loci
discovered using data from the KORA-S4 sample (the largest
population-based sample within stage 2). The explained variance
of WC was estimated to be 0.05% for rs987237 (TFAP2B) and
0.04% for rs7826222 (MSRA). This corresponds to absolute WC
effect sizes of 0.49 and 0.43 cm respectively (as estimated across all
population based samples in stage 2). The SNP near LYPLAL1
(rs2605100) explains 0.02% of the WHR variance in women
(absolute effect size on WHR of 0.0014).
Associations with Adverse Health Consequences
The accumulation of central adiposity has serious adverse
health consequences including hyperlipidemia and increased risks
of T2D. We examined the relationships between adiposity-related
SNPs and these clinical phenotypes using available GWAS meta-
analysis data (Text S1). We found an association between the
WHR-increasing G-allele of rs2605100 (LYPLAL1) and increased
fasting triglycerides (P=3.9610
24; Table S8) in data from a
recent GWAS meta-analysis of 14,343 European samples [28].
This is further supported by a parallel GWAS meta-analysis effort
in 19,840 samples where the G allele is similarly associated with
increased triglycerides (P=0.02) [29]. Using T2D case-control
data from the DIAGRAM consortium [30], we found direction-
ally-consistent, though only weak, associations with T2D-risk,
most obviously at TFAP2B (P=0.09; Table S9). An association
between other non-HapMap TFAP2B variants and T2D has
previously been reported in Japanese samples [21]. These T2D-
associated variants show modest linkage disequilibrium to our WC
associated SNP in UK samples (IVS1774_G/T and rs987237,
r
2=0.42; intron_1+2093_(A/C) and rs987237, r
2=0.67). Thus,
we see some evidence that the variants identified have anticipated
effects on downstream phenotypes, although, as recently demon-
strated for FTO (which has more marked effects on adiposity than
the signals described here), analyses of this type have only limited
power even in extremely large data sets [31].
In summary, by focusing on anthropometric measures of central
obesity, we have identified three loci strongly implicated in the
regulation of human adiposity and fat distribution. The extent of
phenotypic variation explained by these variants is small.
However, the variant or variants at each locus which are directly
involved in influencing these traits are yet to be identified, and
these may have more substantial effects. Even if this is not the case,
effect size has very little bearing on the biological pertinence of
these findings nor the potential impact of perturbing these
pathways through therapeutic modification. Although determina-
tion of the influence of these signals on the development and
maintenance of specific fat depots will require analyses that relate
genetic variation to detailed imaging data in large numbers of
subjects, the loci identified appear to highlight a variety of novel
mechanisms involved in the regulation of adiposity. At this stage, it
is unclear to what extent these same loci influence fat distribution
in other ethnic groups, such as South Asians, in which patterns of
fat distribution, and the relationships between fat distribution and
metabolic disturbance, differ from those in Europeans. The data
are consistent with a model whereby fat mass and distribution are
determined through the concerted action of processes acting at the
level of both the hypothalamus and peripheral fat depots.
Methods
Study Design Summary
Our study began with a genome-wide screen for discovery of
loci potentially associated with two different anthropometric
measures of central adiposity: waist circumference (WC) and
waist-hip-ratio (WHR) [1]. For each of the traits we combined the
summary statistics of 16 genome-wide association studies (GWAS)
in meta-analyses with 38,580 (WC) and 37,670 (WHR) individ-
uals, respectively (stage 1). These studies included nine population-
based cohorts, four case cohorts (three for T2D and one for
Hypertension), and three control cohorts (two originally paired
Meta-Analysis Identifies Adiposity Loci
PLoS Genetics | www.plosgenetics.org 8 June 2009 | Volume 5 | Issue 6 | e1000508with T2D and one with Breast Cancer) (Table S3). Following the
discovery GWA meta-analysis, follow-up of our top association
signals involved: (a) addition of data for markers of interest from
studies with pre-existing ‘‘in-silico’’ GWA results (stage 2a; eight
cohorts, maximum 13,830 individuals) and (b) ‘‘de novo’’ genotyp-
ing (stage 2b; 20 cohorts, maximum 56,859 individuals) giving a
total of 70,689 (WC) or 61,612 (WHR) follow-up samples
(collectively referred to as stage 2). In addition, genome wide
signals for WC identified after stage 2 were confirmed using data
with The Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) consortium, whose meta-analysis
included eight studies totaling 31,375 individuals. All samples
included in these analyses were of European ancestry. We also
undertook gender specific analysis of the stage 1 GWAS. An
overview of the study design and results is given in Figure 1.
Genome-Wide Association Meta-Analysis (Stage 1)
Studies and phenotypes. All samples in the discovery
cohorts were of European ancestry and detailed information on
each of these studies is provided in Tables S3 and S4. Although we
do not have specific age cut-offs for the individual cohorts the
study participants are all adult (mean age between all
cohorts=55.7 years, range 31–70.3 years). All individuals
provided informed consent and all studies were approved by
local ethics committees.
Choice of phenotypes. The most appropriate adiposity
measurements for assessing various fat compartments and the
risk of adverse health outcomes is debated. Despite the close
correlation between WC and BMI (Table S1), WC has been
reported to have a BMI-independent impact on risk of death [1].
WHR is less strongly correlated to BMI than WC (Table S1) and is
used as a more specific surrogate for fat distribution [1]. In our
largest population based samples we see (as expected) that
measures of central and overall adiposity are highly-correlated
(BMI has r
2,0.9 with WC and ,0.6 WHR, Table S1). When
compared to the gold standard of MRI measures of central
adiposity, WC and WHR are equally well-correlated to central
adiposity (r
2,0.6, and 0.5, respectively) as are measures involving
DXA (r
2,0.6) [4].
WC and WHR were measured in the individual cohorts using
standard protocols. Recently a multi-centre comparison of WC
measurements at different sites showed that the measurement at
different centres have no substantial influence on the association to
various adverse health outcomes [32]. In line with this we detect
little, if any, heterogeneity at our significant associations, which
indicates that it is unlikely that any differences in measurement
protocols are having a substantial effect on these (Table S2).
Genotypes and imputation. Operational details of each of
the 16 GWAS (including genotyping platforms, quality control
filters for individuals and SNPs, and imputation and data analysis
methods) can be found in Table S5. In summary, stage 1
genotypes were derived using different genotyping platforms;
Affymetrix 500 k, Illumina HumanHap 550, Illumina
HumanCNV-370DUO, Illumina HumanHap300 Duo Infinium,
or Illumina HumanHap 300. To obtain a marker set that was
common to all studies, and to increase overall coverage of the
whole genome, we imputed all SNPs reported in the CEU sample
in HapMap Phase II using imputation algorithms, yielding a
maximum of 2,573,738 million SNPs available for analysis in one
or more studies. Imputations were performed after excluding
samples and SNPs that did not meet the study-specific quality
control criteria. Genotypes were imputed for SNPs not present in
the genome-wide arrays or for those where genotyping had failed
to meet the QC criteria. We used either of two different software
packages for the imputation: MACH [33] (http://www.sph.
umich.edu/csg/abecasis/MACH/index.html) and IMPUTE [34]
(http://www.stats.ox.ac.uk/,marchini/software).
Quality control (QC) criteria for SNPs to be included in the
meta-analysis were minor allele frequency (MAF)$1% and for
imputed SNPs good imputation quality, which was defined as
proper_info$0.4 (for studies analysed with IMPUTE) or rsq-
hat$0.3 (for studies analysed using MACH). The rsq_hat measure
allows us to assess imputation accuracy for markers with many
different allele frequencies. In comparison to filters based on the
accuracy of individual genotype calls, it generally translates into a
more stringent standard for rare SNPs and a more lenient
standard for common SNPs. For intuition on how the measure
performs consider the simple example of region where a particular
SNP always occurs in a specific haplotype background. Further,
assume that the SNP has a frequency of 10% and that the
haplotype has a frequency of 20%. In this example, whenever we
observed this particular haplotype we expect the SNP will be
present ,50% of the time so that .50% imputation accuracy
cannot be achieved for this SNP. On the other hand, knowledge of
the haplotype does provide useful information about the SNP, and
the rsq_hat statistic takes a value of about 0.44 in this setting.
There are examples of association between imputed SNPs with
similar rsq_hat statistics and complex traits that have been
confirmed in follow-up genotyping (e.g. the association between
CETP and HDL cholesterol) [16].
The studies analysed with IMPUTE typically used an
additional filter to exclude imputed genotypes with a posterior
probability ,0.9 for IMPUTE. The proper_info measurement is
interpretable as a value of x (between 0 and 1) means
(approximately) that the amount of statistical information (about
the parameter of interest in the model) at the imputed SNP is
equivalent to perfect genotype data in a sample 1006% as big
as the used sample size.
Empirical assessments show that genotype imputation using
either MACH or IMPUTE provides an effective and accurate
means of evaluating evidence for association at untyped markers
[Li et al, Ann Rev Genom Hum Genet, in press; [35–37].
Furthermore, imputation is typically accurate even for strongly
associated markers (see the Text S1 [16,38]).
Study-specific stage 1 GWAS analysis. The GWAS
analysis was performed by each study applying a standardized
phenotype transformation to WC or WHR, respectively. Subjects
were stratified by gender and the gender-specific rank of either the
raw phenotype data or the residuals of a linear regression of the
raw phenotype on age and age
2 were inverse-normal transformed
to yield normally distributed phenotypes. In case-control studies,
cases and controls were analyzed separately. The additive genetic
effect for each genotyped or imputed SNP was estimated using a
linear regression model. For studies where the inverse-normal
transformation was performed on raw phenotypes rather than
residuals of the phenotype, age and age
2 covariates were included
in these tests. Some studies used association testing which takes
genotype and imputation uncertainty into account using a missing
data likelihood test implemented using SNPTEST [34] (http://
www.stats.ox.ac.uk/,marchini/software) or by using allele
dosages as the independent variable in the linear regression
model in MACH2QTL [33] (http://www.sph.umich.edu/csg/
abecasis/MACH/download/). To account for the clear gender
dimorphism in these traits, analyses were performed in men and
women separately, apart from the SardiNIA and deCODE studies
for which, due to family relatedness between men and women, a
combined analysis of men and women together was also
performed, which accounted both for relatedness and gender in
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MACH2QTL [33], Merlin [39] and SNPTEST [34] were used.
Meta-analysis of GWAS results. Results from the genome-
wide analyses were meta-analysed by combining the separate
results for men and women (or the combined gender results in the
case of SardiNIA and deCODE) from each study together into one
meta-analysis of overall effect for each phenotype (mixed-gender
analysis).
Two methods were used in parallel for stage 1 meta-analyses.
The first analysis approach we used was the weighted Z-method,
which allows P-values and direction of effect to be combined
independently of b-estimates, allowing for incompatibility between
phenotype units as in the Fisher method [40], but with improved
power and precision over Fisher’s test [41]. In this approach,
study-specific P-values and direction of effect are converted into a
signed Z-statistic. These Z-statistics are then summed with weights
proportional to the square root of the sample size for each study.
The other approach we used for our GWAS meta-analysis
combines study-specific b-estimates using the fixed effect model
[42], using the inverse of the variance of the study-specific b-
estimates to weight the contribution of each study. Both meta-
analysis methods are implemented in METAL (www.sph.umich.
edu/csg/abecasis/metal). Results from the two approaches were
highly congruent in terms of P-values. The P-values we report here
are those derived from the former meta-analysis method, as it was
the first we performed and results using this method were used for
the selection of the SNPs taken forward to follow-up. However,
measures of effect size (as b and standard error (SE)) can only be
obtained from the latter.
Before performing either of these methods for a phenotype,
within-study genomic control (GC) correction was applied to Z-
statistics and to the variance of b-estimates using lambda factors
specific to each study calculated separately for each gender (within-
study GC correction) [18]. The GC-correction approach is based on
the lambda factor, which is computed as the median of all
genome-wide observed test statistics (chi-square statistic) divided
by the expected median of the test statistic under the null
hypothesis of no association (making the assumption that the
number of true associations is very small compared to the millions
of tests performed). For each study-gender combination, the
observed test statistic at each SNP was divided by the lambda
factor to obtain GC corrected results.
After performing each meta-analysis, we again calculated a
lambda factor based on the distribution of overall test statistics, i.e.
from b-estimates and SE based on the fixed effect method or on
the Z-score from the weighted Z-score method. The overall
lambda factors in the mixed-gender analysis were lGC_WC=1.09
and lGC_WHR=1.07 for the waist phenotypes. GC correction
based on these overall lambda factors was then also applied (overall
GC correction). We also found it informative to calculate lGC_1000,
which is an adjusted inflation factor for an equivalent study of
1,000 cases and 1,000 controls which can be calculated by
rescaling lGC as previously described [19]. The results for the
mixed-gender analysis for these adjusted inflation factors were
lGC_WC_1000=1.003 and lGC_WHR_1000=1.002 for the two waist
phenotypes.
Finally, we computed (based on b-estimates and SE) I
2 statistics
and Q-statistic P-values as measures of observed heterogeneity
(Table S2).
SNP selection for replication. We aimed to select SNPs for
replication that were enriched for signals of association with
measures of central adiposity relative to overall adiposity or body
size. To this end, we based our selection of markers for replication
on evidence of association with WC or WHR (measures of central
adiposity and fat distribution), while attempting to avoid
associations that were primarily driven by associations with BMI
(as an index of overall adiposity).
First, we identified SNPs with a P-value#10
25 in the
preliminary analyses with at least one of the phenotypes. This
set of SNPs was then separated into independent loci by taking
the most significantly associated SNP and eliminating all SNPs
that have a HapMap CEU pair-wise correlation coefficient
(r
2).0.2 with that SNP, then proceeding to the next strongly
associated SNP remaining. Seventy-six independent loci each
represented by one main SNP met these criteria in our
preliminary analysis.
Previous experience with genome-wide association studies of
anthropometric traits such as BMI [10,14,16–17,20] and height
[43–46] suggested that large numbers of additional samples would
be required to establish association at levels of genome-wide
significance. We focused our attention on 23 SNPs that showed
strong association with at least one of the waist phenotypes, but
with less significant evidence of association with BMI (p.0.01) and
height (p.0.005), from previous analyses performed of stage 1
GWAS data within the GIANT consortia. These 23 SNPs thus
had significantly stronger evidence of association with the waist
phenotypes in our initial genome wide meta-analysis data than
with BMI or height in previous meta-analyses involving compa-
rable numbers of subjects.
We also added three SNPs that, despite not meeting all the P-
value selection criteria, were near the borderline (Table S2) and
for which biological credentials warranted selection:
(1) rs7970350, which maps very near the HMGA2 (12q15) gene.
In addition to being a strong biological candidate for height,
HMGA2 is a strong biological candidate for obesity; rare
mutations in this gene have previously been shown to alter
body size in mice and humans. Hmga22/2 mice have a
deficiency in fat tissue and resist diet-induced obesity [47].
Furthermore, the expression of a truncated HMGA2 gene
induces gigantism associated with lipomatosis [48]. This
marker is in perfect linkage disequilibrium (LD) (r
2=1) with a
previously described locus for height (rs1042725) [43,45,46].
Given the low correlation between waist-circumference and
height, as well as the obvious candidacy for both height and
obesity, we hypothesized that this loci might affect body shape
(i.e. with independent effects on height and obesity).
(2) rs11970116, which maps ,90 kb upstream of the hypocretin
(orexin) receptor 2 gene, HCRTR2 (6p11-q11). Orexins and
their receptors are good candidate genes for adiposity as the
orexin pathway has been implicated in the control of energy
homeostasis as well as in narcolepsy and sleep patterns (ref
21). It has also been reported that hypothalamic orexin
promotes appetite and that HCRTR2 signaling confers
resistance to diet-induced features of the metabolic syndrome
through negative energy homeostasis and improved leptin
sensitivity [49–51].
(3) rs987237, which maps to intron 3 of the TFAP2B (6p12) gene
to add a second SNP in the vicinity of this locus in addition to
rs4715215 that was already selected as one of our 23 SNPs for
follow-up (pair wise r
2=0.236; D9=1). While rs4715215 is
located ,145 kb downstream of TFAP2B, rs987237 is located
within the gene transcript (Figure 2).
Thus, including both the 23 SNPs meeting our filtering criteria
and the three additional variants, we targeted a total of 26
independent SNPs for replication in additional samples. As there
were some SNPs for which the stage 1 association met the selection
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analyses to be performed (see Tables S2 and S6).
Follow-Up in Independent GIANT Consortium Samples
(GIANT Stage 2)
Studies and phenotypes. For our own Stage 2 analysis, we
sought follow-up samples from two independent routes: we
included studies with pre-existing GWAS in-silico data (stage 2a)
as well as de novo genotyping (stage 2b) comprising 27 cohorts for
WC and 21 cohorts for WHR. Among these stage 2 studies, 18
studies were also able to provide data on BMI, weight, and height.
All individuals included in stage 2 studies were of European
ancestry and provided informed consent. All studies were
approved by the local ethics committees. Study-specific
information on study design and participants, phenotype means,
and experimental detail for all stage 2 studies are included in
Tables S3, S4, S5.
Additional phenotypes. In addition to data on the waist
phenotypes (WC and WHR) and other relevant anthropometric
traits (BMI, weight, and height), we also had some cohorts from
both stage 1 and stage 2 which were able to provide bioimpedance
data (BIA) and/or Dual energy X-ray absorptiometry (DXA). In
stage 1, three studies were informative for BIA (maximum
N=9,852), and two (maximum N=2,308) had data on DXA.
In stage 2, a total of seven cohorts had BIA (maximum N=20,934)
and six had DXA data (maximum N=12,954). Thus, the total
sample size for BIA and DXA was 30,786 or 15,262, respectively.
Genotypes. Genotypes were obtained from stage 2a studies,
in which each SNP was either directly genotyped or imputed from
genome-wide data using the CEU HapMap reference panel, and
from stage 2b using de novo genotyping undertaken using a variety
of platforms including Biotrove, Centaurus, KASPar, Sequenom,
Sequenom iPLEX, and TaqMan-based assays.
Genotyping platforms, calling algorithms, quality control before
imputation, imputation methods, and analysis software used were
all study-specific (see Table S5 for detailed information on each
study). The explicit number of follow-up SNPs genotyped in each
study and whether a proxy SNP was used is summarized in Table
S6.
Study-specific stage 2 association analyses. To analyze
the two waist phenotypes in the stage 2 studies, we used the same
analysis model as in stage 1 (inverse-normal transformed WC or
WHR adjusted for age and age
2 analyzed in a linear regression, all
performed separately in men and women).
Additional analyses were performed - all separately in men and
women and all using an additive genetic effect model - to obtain:
N waist phenotype association independent from overall obesity
(using inverse-normal transformed WC or WHR adjusted for
age, age
2 and BMI)
N raw estimates of effect sizes for WC and WHR (using
untransformed WC or WHR, adjusted for age and age
2)
N raw estimates of BMI effect sizes (using untransformed BMI
adjusted for age and age
2)
N association estimates in studies with % fat phenotypes (using
untransformed % total fat BIA, % total fat DXA, % central
fat DXA adjusted for age and age
2).
GIANT Stage 2 meta-analyses. We performed a meta-
analysis for the phenotypes of primary interest (WC and WHR) of
all stage 2 studies using the same methods as in stage 1 (pooled P-
values using the weighted Z-score method; pooled b- and SE
estimates using the fixed effect method; as well as heterogeneity
statistics).
Meta-analysis of all GIANT data (stage 1+stage 2). We
combined GIANT stage 1 and stage 2 samples to derive a
combined meta-analysis of all studies, performed in the same
manner as in stage 1 and stage 2 analyses. Results from stage 1 and
stage 2 studies were combined into one N-way meta-analysis.
Five of the 26 loci that were selected for follow up show nominal
evidence of association with both WC and WHR (TFAP2B
(rs987237) was one of these). However, for none of these loci did
the association with WHR reach genome-wide significance in the
overall, combined analysis (Table S2).
GIANT Gender-specific meta-analysis (stage 1, stage 2,
and stage 1+2). The waist phenotypes exhibit strong gender-
differences and evidence for some genetic effects on fat distribution
[7], so we performed additional meta-analyses of our stage 1
GWAS in which men and women were analyzed separately. We
also tested whether the effect estimate resulting from the gender-
specific fixed effect meta-analysis differed significantly between
men and women by applying a t-test comparing b-effect and SE
estimates in men with the b-effect and SE estimates in women.
The gender-specific meta-analyses were performed on stage 1,
stage 2, and combined stage 1+2 data.
Additional Replication through Further Follow-Up Using
In Silico Results from the CHARGE Consortium
Further, our genome wide signals for WC identified after stage 2
were confirmed using data from the ‘‘Cohorts for Heart and Aging
Research in Genomic Epidemiology’’ (CHARGE) consortium,
which members had performed a GWAS meta-analysis of 31,375
samples for WC (Table 1).
Studies, phenotypes, and genotypes. The CHARGE
consortium consisted of 31,375 individuals from 8 studies
informative for WC, though two studies overlapped with our
stage 2a studies (the Erasmus Rucphen Family Study (ERF) and
the Rotterdam Study (ERGO), (up to 6,702 individuals) which
were included in both CHARGE and stage 2 data, but which are
counted only once in the overall meta-analysis.
Meta-analysis of stage 1+2 results with CHARGE
data. We combined the association results for WC from the
GIANT and CHARGE samples to derive a combined meta-
analysis of all studies (Figure 1). This analysis was performed using
the METAL software for pooling of the P-values based on the
weighted Z-score method, using the P-values calculated in our
stage 1+2 meta-analysis (excluding ERF and ERGO) along with
the P-values from CHARGE. For a more detailed description of
the CHARGE consortium studies and their analysis methods,
([Fox et al. submitted to PLOS Genetics (2008)] and [http://web.
chargeconsortium.com/]).
For the MSRA locus, genotypes for rs7826222 were only
available for a subset of the CHARGE samples (N=8,097). This is
due to the fact that this SNP has been renamed to rs545854 in
NCBI build 36 and was consequently one of the SNPs omitted
from HapMap release 22 and therefore is not present in build 36
imputations based on that release of HapMap. Nonetheless, the
effect of rs7826222 in CHARGE was directionally-consistent
(P=0.28), and CHARGE data available in larger sample size
(N=31,372) for two moderately-good proxies (rs1876511 and
rs613080, both r
2=0.76 with rs7826222/rs545854) and both
show some support (both had directionally-consistent effect-sizes
and P=0.078) with the other findings.
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